Literature DB >> 7506190

Tolerability of nimesulide. Epidemiological data.

G Fusetti1, E Magni, M C Armandola.   

Abstract

This review describes the tolerability profile of nimesulide as documented in a global assessment of the clinical data available to Helsinn for this drug. Data from 151 trials were considered and the relevant case report forms and study reports were used as source information. The analysis was conducted using between-treatment and within-treatment comparisons. The between-treatment comparison included data derived from placebo-controlled trials, while the within-treatment comparison included nimesulide data only. Of 4945 subjects treated with nimesulide, 349 (7.1%) experienced adverse events and 52 (1.1%) withdrew from treatment. The most frequently reported adverse events were those related to the digestive system, body as a whole, skin and nervous system. The incidence and nature of adverse events observed for nimesulide-treated patients were similar to those of the placebo group. Nimesulide was particularly well tolerated by the liver, lungs, kidneys and blood.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7506190     DOI: 10.2165/00003495-199300461-00070

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  2 in total

1.  Design, monitoring, and analysis issues relative to adverse events.

Authors:  K E Peace
Journal:  Drug Inf J       Date:  1987

2.  Statistical analyses of adverse event data from clinical trials. Special emphasis on serious events.

Authors:  R T O'Neill
Journal:  Drug Inf J       Date:  1987
  2 in total
  5 in total

1.  Multiple enterocolic perforations and their possible association with prolonged intake of nimesulide: report of two cases.

Authors:  Corrado Rosario Asteria; Giacomo Batignani; Alessandro Garcea; Francesco Tonelli
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

2.  Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in Greece.

Authors:  L Liaropoulos; M Spinthouri; T Ignatiades; G Ifandi; F Katostaras; E Diamantopoulos
Journal:  Pharmacoeconomics       Date:  1998-11       Impact factor: 4.981

3.  An analysis from clinico-epidemiological data of the principal adverse events from the COX-2 selective NSAID, nimesulide, with particular reference to hepatic injury.

Authors:  K D Rainsford
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

Review 4.  Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  R Davis; R N Brogden
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

5.  The effects of etodolac, nimesulid and naproxen sodium on the frequency of sister chromatid exchange after enclused third molars surgery.

Authors:  Banu Gurkan Koseoglu; Sukru Ozturk; Hulya Kocak; Sukru Palanduz; Kivanc Cefle
Journal:  Yonsei Med J       Date:  2008-10-31       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.